— Julie Desander

Patents/USRE049435

USRE049435No. USRE049435reissueGranted 2/28/2023

Claims (21)

Claim 1 (Independent)

1. A method of reducing tumor volume comprising administering an antibody that specifically binds to sialyl Tn antigen (STn) to a subject, wherein said subject has a tumor comprising STn, wherein said antibody is administered at a dose of from about 0.25 mg/kg to about 25 mg/kg, and wherein said antibody comprises: a heavy chain variable domain (VH) comprising: a complementarity determining region (CDR)-H1 comprising the amino acid sequence of SEQ ID NO: 143 81 : a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 146 84 ; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 153 96 ; a light chain variable domain (VL) comprising: a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 161 108 ; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 123; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 135; and a conjugated cytotoxic agent,

Claim 9 (Independent)

9. A composition comprising: (a) an antibody that specifically binds to sialyl Tn antigen (STn), said antibody comprising: a VH comprising: a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 143 81 ; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 146 84 ; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 153 96 ; and a VL comprising: a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 161 108 ; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 123; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 135; and (b) an excipient, said excipient comprising from about 2 mM to about 100 mM citrate and from about 10 mM to about 300 mM NaCl.

Claim 11 (Independent)

11. A method of treating cancer that expresses sialyl Tn antigen (STn) comprising administering a composition to a subject, wherein said subject comprises at least one cancer cell that expresses STn, and wherein said composition comprises: (a) an antibody that specifically binds to STn comprising: a VH comprising: a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 143 81 ; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 146 84 ; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 153 96 ; a VL comprising: a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 161 108 ; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 123; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 135; and a conjugated cytotoxic agent; and (b) an excipient, said excipient comprising from about 2 mM to about 100 mM citrate and from about 10 mM to about 300 mM NaCl,

Claim 15 (Independent)

15. A method of treating cancer that expresses sialyl Tn antigen (STn) comprising administering an antibody that specifically binds to STn to a subject, wherein said subject includes at least one cancer cell that expresses cell surface STn, wherein said antibody is administered at a dose of from about 0.25 mg/kg to about 25 mg/kg, and wherein said antibody comprises: a VH comprising: a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 143 81 ; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 146 84 ; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 153 96 ; a VL comprising: a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 161 108 ; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 123; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 135; and wherein said antibody comprises an Fc region capable of promoting antibody-dependent cell-mediated cytotoxicity, antibody-dependent cell phagocytosis, and/or complement-dependent cytotoxicity directed against said at least one cancer cell in said subject or wherein said antibody includes a conjugated cytotoxic agent,

Show 17 dependent claims

Claim 2 (depends on 1)

2. The method of claim 1 , wherein said antibody is a monoclonal antibody.

Claim 3 (depends on 1)

3. The method of claim 1 , wherein said antibody comprises an IgG1 isotype.

Claim 4 (depends on 1)

4. The method of claim 1 , wherein said antibody comprises an IgG2 isotype.

Claim 5 (depends on 1)

5. The method of claim 1 , wherein said conjugated cytotoxic agent comprises monomethyl auristatin E.

Claim 6 (depends on 1)

6. The method of claim 1 , wherein tumor volume in said subject is reduced by at least 20%.

Claim 7 (depends on 6)

7. The method of claim 6 , wherein tumor volume in said subject is reduced by from about 80% to about 99%.

Claim 8 (depends on 7)

8. The method of claim 7 , wherein said conjugated cytotoxic agent comprises monomethyl auristatin E.

Claim 10 (depends on 9)

10. The composition of claim 9 , wherein said antibody is conjugated to a drug.

Claim 12 (depends on 11)

12. The method of claim 11 , wherein said conjugated cytotoxic agent comprises monomethyl auristatin E.

Claim 13 (depends on 1)

13. The method of claim 1 , wherein STn is present on the surface of at least one cell of said tumor comprising STn.

Claim 14 (depends on 11)

14. The method of claim 11 , wherein STn is present on the surface of said at least one cancer cell that expresses STn.

Claim 16 (depends on 15)

16. The method of claim 15 , wherein said antibody includes a conjugated cytotoxic agent, wherein said conjugated cytotoxic agent is conjugated directly or via a linker.

Claim 17 (depends on 16)

17. The method of claim 16 , wherein said conjugated cytotoxic agent comprises a cytoskeletal inhibitor.

Claim 18 (depends on 17)

18. The method of claim 17 , wherein said cytoskeletal inhibitor is monomethyl auristatin E.

Claim 19 (depends on 10)

19. The composition of claim 10 , wherein said drug is conjugated directly or via a linker.

Claim 20 (depends on 19)

20. The composition of claim 19 , wherein said drug is a cytotoxic agent.

Claim 21 (depends on 20)

21. The composition of claim 20 , wherein said cytotoxic agent is monomethyl auristatin E.

Full Description

No description text available for this patent.

Citations

This patent cites (324)

US4179337
US4301144
US4444887
US4474893
US4485045
US4496689
US4544545
US4640835
US4670417
US4695198
US4714681
US4716111
US4791192
US4816397
US4816567
US4900727
US4925648
US4946778
US4975369
US4978745
US5013556
US5045532
US5059680
US5091513
US5158886
US5208020
US5225539
US5258498
US5403484
US5413923
US5427908
US5475092
US5516637
US5530101
US5565332
US5571698
US5573920
US5580717
US5585089
US5585499
US5601819
US5625126
US5633425
US5658727
US5693761
US5693762
US5698426
US5710038
US5733743
US5733920
US5750753
US5780225
US5786464
US5807715
US5811510
US5821047
US5846545
US5849733
US5863990
US5902725
US5919652
US5932448
US5939598
US5951983
US5958398
US5969108
US6075181
US6114148
US6114598
US6180370
US6300129
US6348584
US6673901
US6852533
US6872868
US6936612
US7119200
US7208489
US7345171
US7456168
US7569390
US7608453
US7682794
US7749225
US7820797
US7855211
US7863278
US7884054
US7897347
US7994100
US8084219
US823244
US8232448
US8298773
US8399625
US8440798
US8506966
US8524214
US8541231
US8685383
US8685980
US8808679
US8980311
US9193732
US9254339
US9273142
US9423401
US9555112
US9718888
US9879087
US11028181
US20020012660
US20020192231
US20030104402
US20030108548
US20030212027
US20030235850
US20040047891
US20040115740
US20050084903
US20050272107
US20050276800
US20050288492
US20060034834
US20070048314
US20070059769
US20070089178
US20070116727
US20070265170
US20070275409
US20080019968
US20080166805
US20080193453
US20080253963
US20080279847
US20090041783
US20090099073
US20090196916
US20090221803
US20090280116
US20090280128
US20090326203
US20100009424
US20100034825
US20100075344
US20100104572
US20100143939
US20100178292
US20100196983
US20100221770
US20100272707
US20100278818
US20100292095
US20100293624
US20110081356
US20110135570
US20110143373
US20110177614
US20110195921
US20120027813
US20120039984
US20120045816
US20120114652
US20120142903
US20120164068
US20120177664
US20130011868
US20130017200
US20130039991
US20130108624
US20130177579
US20130236486
US20140005069
US20140106449
US20140113979
US20140178365
US20150110789
US20150314008
US20150368349
US20160022829
US20160130356
US20160168211
US20160220696
US20170305950
US20170306046
US20180037663
US20180280504
US20180327509
US20190031780
US20190276541
US20200000932
US20200041517
US20200247902
US20200276306
US20210011021
US20210017213
US0239400
US0316818
US0313244
US0404097
US0519596
US0316818
US0592106
US0404097
US2287202
US2422811
US2565268
US2703485
US3091032
US1990002809
US1991000360
US1991009967
US1991010737
US1991010741
US1991019739
US199201047
US1992/005793
US1992008802
US1992018619
US1993011161
US1993011236
US1993017715
US1995015982
US1995/020401
US1995015982
US1996033735
US1996034096
US1998016654
US1998024893
US1998046645
US1998050433
US1998050433
US1999/014353
US1998046645
US2000/023573
US2000/054057
US2011/003896
US2001/043778
US2001040276
US2002/035237
US2002/077029
US2002/086096
US2002/086505
US2002/088334
US2002/088351
US2003/008451
US2003/014960
US2003016329
US2003/040185
US2003/062415
US2003/077945
USWO2003/086276
US2003/095641
US2003/097697
US2004/046185
US2004/046186
US2004/046187
US2004/046188
US2004/046189
US2004/046192
US2003062415
US2004/099775
US2003097697
US2005/010485
US2005/033303
US2003086276
US2005/088310
US2006002382
US2006002382
US2006/133356
US2006/1333356
US2007/059298
US2008040362
USWO2008/070363
US2009/018438
US2008040362
US2009035494
US2009035494
US2009060129
USWO2009/091826
US2010/004432
US2010030666
US2010/065818
US2013151649
US2011/003896
US2011/041093
US2011/088385
US2011089004
US2012/007167
US2012009474
US2012/048332
US2012/079000
US2012094627
US2012106465
US2013/023251
US2013/033420
US2013/040557
US2013/055404
US2013/074916
US2013/092001
US2013/126712
US2013/138795
US2013151649
US2014/028560
US2014/030780
US2014/039513
US2014/055771
US2014/106639
US2014105810
US2014/144357
US2014/144573
US2015048748
US2015054600
US2015134488
US2015159076
US2016033284
US2016057916
US2016077526
US2016090034
US2016149368
US2016201240
US2017083582
US2018094143
US2018094144